Whalesbook
Okay, toh Natco Pharma ka stock kaafi time se ₹1051-₹1059 ke level par atak raha tha, par aaj usko seedha tod diya!
Aur mazedaar baat ye hai ki trading volumes bhi 30-day average se lagbhag double the, matlab logon ka bharosa dikh raha hai. Technicals bhi positive hain, jaise ki golden crossover aur ADX 24.93 pe chal raha hai, jo bullish momentum dikhata hai. Abhi company ki market cap lagbhag ₹19,400 crore ke aas paas hai.
Sahi khel ho gaya - Sasti Dawa aur Business Split!
Ab is move ke peeche ke reasons dekhte hain. Pehle, Natco Pharma ne ekdum affordable Semaglutide Injection launch kiya hai India mein, woh bhi multi-dose vials mein! Ye India mein pehla case hai. Price itna kam hai ki pen devices se 70% tak sasta aur original brand se toh 90% kam hai. Socho, India mein jo itne saare log diabetes aur obesity se suffer kar rahe hain, unke liye ye access karna kitna easy ho jayega. Analyst log predict kar rahe hain ki Indian GLP-1 market 2030 tak paanch guna tak badh sakta hai, khaskar jab Semaglutide patents expire ho gaye hain March 2026 mein.
Aur dusra bada move hai company ke agrochemical business ko spin off karna. Board ne approve kar diya hai ki ye ek nayi company, Natco Crop Health Sciences Ltd., ke naam se alag hogi. Shareholders ko har one share ke badle us nayi company ka bhi one share milega. Ye sab operations ko simplify karne aur alag alag value unlock karne ke liye kiya ja raha hai.
Valuation bhi mast, competitors se toh bahut saasta!
Jab baat valuation ki aati hai, toh Natco ka P/E ratio lagbhag 12.45 hai, jo Sun Pharma (33.97), Divi's Laboratories (61.42) aur Dr. Reddy's Laboratories (17.94) jaise competitors ke muqable bahut kam hai. Aur ye toh tab hai jab stock ne pichle ek saal mein 41.33% ka return diya hai aur profit growth 41.62% rahi hai! Balance sheet bhi ekdum fit hai, debt-to-equity ratio sirf 0.03 hai.
Analyst kya bol rahe hain? Thoda Confusion hai boss!
Par haan, sabko ye rally pasand nahi aa rahi. Analysts ki rai mili-juli hai. Consensus rating 'Neutral' hai aur unka average 12-month price target ₹987 hai, jo current level se lagbhag 4% kam hai. Kuch analyst reports toh aagey 3 saal mein earnings aur revenue kam hone ka bhi andaza laga rahi hain. Unhein lagta hai ki itne kam price pe dawa bechne se long-term profitability par question hai. Aur agrochemical business ko alag karne mein bhi kuch challenges ho sakte hain. History mein bhi dekha gaya hai ki aisi sharp rallies ke baad stock consolidate karta hai.